ATAI Healthcare · Clinical stage · Mental health · Pending acquisition · Thesis updated August 16, 2026

Eli Lilly buyout brings cash and milestone upside

Written by Finn ResearchReviewed by Shivam BharukaReviewed August 16, 2026

Eli Lilly agreed to buy the company for $6.75 per share in cash.
Shareholders also get contingent value rights worth up to $2.50 per share based on drug trials.
If the merger fails, the company faces a $104.3 million termination fee.
The lead drug, BPL-003, has officially initiated Phase 3 testing for depression.
The deal removes much of the standalone cash risk if it closes in Q3 2026.

01 Running thesis

A clinical bet turns into an acquisition

Atai Beckley is a high-risk biotech built around new mental health drugs. The company recently agreed to be acquired by Eli Lilly. This changes the entire investment story.

The bull case is now tied to the buyout. Shareholders will receive $6.75 per share in cash when the deal closes, which is expected in Q3 2026. This removes the heavy risk of funding expensive clinical trials alone. Investors also get contingent value rights, or CVRs, that could pay out up to $2.50 more per share if certain drugs hit specific milestones.

The bear case centers on the deal breaking. If the merger fails to close, Atai Beckley must pay a $104.3 million termination fee under certain conditions. The company would then revert to a standalone biotech with high cash burn and complex regulatory hurdles for its psychedelic therapies.

Beyond the closing date, the main catalysts are clinical. BPL-003 has initiated its Phase 3 program for treatment-resistant depression. Progress on this and the VLS-01 program will determine if the CVRs ever pay out.

Aug 2026▲Eli Lilly agreed to acquire the company for $6.75 per share in cash plus contingent value rights. This materially shifts the focus from standalone cash burn to merger completion.

May 2026→The Q1 2026 filing kept the main thesis intact. It confirmed the BPL-003 Phase 3 design, including ReConnection-1, ReConnection-2, and the Week 4 MADRS primary endpoint.

Mar 2026→Coverage began with the 2025 10-K. The setup was a high-upside mental health pipeline balanced against large losses, no approved core drugs, and psychedelic regulatory risk.

02 Business model

Mostly research, soon to be part of Lilly

Atai Beckley does not make money from selling its main drug candidates today. Its core business has been spending money on research, manufacturing, and clinical trials so those drugs can reach regulators.

The small revenue that does exist comes from Nualtis, a wholly owned subsidiary. Nualtis is a contract development and manufacturing organization. It helps other drug companies with oral thin film technology and pharmaceutical research services.

Once the Eli Lilly acquisition closes, Atai Beckley will survive as a wholly owned subsidiary. Until then, the company continues to operate its pipeline and fund its trials. The buyout agreement greatly reduces the pressure to raise cash in the public markets.

03 Product portfolio

The pipeline driving the buyout

Growth engine

BPL-003

BPL-003 is a nasal spray drug for treatment-resistant depression. It is the lead asset, has initiated Phase 3 activities, and is tied to the contingent value rights.

Option

VLS-01

VLS-01 is a buccal film form of DMT for treatment-resistant depression. Its progress into later stage testing is also key to unlocking the CVR payments.

Option

EMP-01

EMP-01 is an oral R-MDMA program for social anxiety disorder. Phase 2a results previously showed improvement across multiple symptom measures.

Steady

Nualtis oral thin film technology

Nualtis provides license and research services using oral thin film drug delivery technology. It brings in small amounts of revenue today.

04 Business segments

Revenue is tiny and service-led

Nualtis license and R&D services100%flat

Core clinical pipeline product sales0%flat

This mix uses reported revenue lines from Q1 2026. The core clinical pipeline had no product sales, so all reported revenue came from Nualtis license and research services.

05 Risk factors

What could break the story

The Eli Lilly merger fails

High impact · Low odds

The biggest risk is that the acquisition does not close. If the deal breaks under specified circumstances, Atai Beckley must pay a $104.3 million termination fee. This would crush the stock and return the company to a cash-burning standalone business.

We watchStockholder vote outcomes, regulatory approvals, and updates on the expected Q3 2026 closing date.

CVRs expire worthless

Medium impact · Medium odds

The extra $2.50 per share is not guaranteed. It requires BPL-003 and VLS-01 to hit specific clinical and regulatory milestones. If regulators push back or trials fail, the contingent value rights will pay out nothing.

We watchInitiation of VLS-01 Phase 3, regulatory feedback, and BPL-003 trial updates.

Psychedelic regulation slows progress

High impact · Medium odds

These drugs may raise extra questions for regulators because some are psychedelic-based therapies. Regulators may ask for more safety data or stricter patient monitoring. That could delay approval and threaten the milestone payments.

We watchFDA feedback, trial protocol changes, and any request for extra safety studies.

Cash burn outruns the runway

High impact · Low odds

If the deal breaks, cash burn becomes a massive problem again. The company reported a $29.8 million net loss in Q1 2026. A failed deal plus the termination fee would severely shorten the cash runway.

We watchUpdates on the merger close and quarterly cash balances.

06 Quick answers

In one breath

Is Atai Beckley being acquired?

Yes. Eli Lilly agreed to acquire the company for $6.75 per share in cash, plus a contingent value right that could pay up to $2.50 more.

What is a contingent value right (CVR)?

It is an extra payment to shareholders if the company hits certain goals. For Atai Beckley, the CVR pays out if its key depression drugs reach specific clinical and regulatory milestones.

Does Atai Beckley have any approved drugs?

No. Its core mental health drugs are still in clinical development. BPL-003, the lead program, is currently in Phase 3 trials.

What happens if the buyout fails?

If the deal breaks under certain conditions, Atai Beckley must pay Eli Lilly a $104.3 million termination fee. The company would remain an independent, unprofitable biotech.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed: August 16, 2026
Score data: September 6, 2026
Reviewed by: Shivam Bharuka

08 Explore the industry

Comparable Biotechnology companies

Companies near Atai Beckley Inc. in Finn's Biotechnology industry ranking.

ARWR Arrowhead Pharmaceuticals, Inc. Company research BHVN Biohaven Ltd. Company research ARGX argenx SE Company research BLTE Belite Bio, Inc Company research APLS Apellis Pharmaceuticals, Inc. Company research BPMC Blueprint Medicines Corp. Company research